[go: up one dir, main page]

MX2023003754A - Formulacion farmaceutica para inhalador presurizado de dosis medidas. - Google Patents

Formulacion farmaceutica para inhalador presurizado de dosis medidas.

Info

Publication number
MX2023003754A
MX2023003754A MX2023003754A MX2023003754A MX2023003754A MX 2023003754 A MX2023003754 A MX 2023003754A MX 2023003754 A MX2023003754 A MX 2023003754A MX 2023003754 A MX2023003754 A MX 2023003754A MX 2023003754 A MX2023003754 A MX 2023003754A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
metered dose
dose inhaler
pressurised metered
pharmaceutical composition
Prior art date
Application number
MX2023003754A
Other languages
English (en)
Inventor
Sauro Bonelli
Diego Copelli
Francesca Usberti
Enrico Zambelli
Alberi Massimiliano Dagli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2023003754A publication Critical patent/MX2023003754A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/009Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere en general a una composición farmacéutica que comprende un agente de LABA, opcionalmente en combinación con otros ingredientes activos, una mezcla de por lo menos dos ácidos inorgánicos, un propelente y un cosolvente. La invención también proporciona una composición farmacéutica para el tratamiento de enfermedades respiratorias, tales como asma y EPOC.
MX2023003754A 2020-10-09 2021-10-08 Formulacion farmaceutica para inhalador presurizado de dosis medidas. MX2023003754A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20201060 2020-10-09
PCT/EP2021/077827 WO2022074183A1 (en) 2020-10-09 2021-10-08 A pharmaceutical formulation for pressurised metered dose inhaler

Publications (1)

Publication Number Publication Date
MX2023003754A true MX2023003754A (es) 2023-04-24

Family

ID=72826742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003754A MX2023003754A (es) 2020-10-09 2021-10-08 Formulacion farmaceutica para inhalador presurizado de dosis medidas.

Country Status (13)

Country Link
US (1) US20230277451A1 (es)
EP (1) EP4225267A1 (es)
JP (1) JP2023546025A (es)
KR (1) KR20230084482A (es)
CN (1) CN116419749A (es)
AU (1) AU2021356146A1 (es)
CA (1) CA3193038A1 (es)
CL (1) CL2023000998A1 (es)
CO (1) CO2023004162A2 (es)
IL (1) IL301617A (es)
MX (1) MX2023003754A (es)
PE (1) PE20240629A1 (es)
WO (1) WO2022074183A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023227781A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227783A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227782A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ259192A (en) * 1992-12-09 1997-05-26 Boehringer Ingelheim Pharma Aerosol medicament comprising water-sensitive or solvent-sensitive active agent, hfc propellant stabilised by addition of (in)organic acid
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
EA200602112A1 (ru) * 2004-05-13 2007-04-27 Кьези Фармачеутичи С. П. А. Изделие для медицинского аэрозоля
JP5914354B2 (ja) 2009-12-23 2016-05-11 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Copd用併用療法
PE20121467A1 (es) 2009-12-23 2012-11-07 Chiesi Farma Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
HUE039513T2 (hu) 2013-12-30 2019-01-28 Chiesi Farm Spa Glikopirrónium-bromid és formoterol kombinációját tartalmazó nyomás alatti stabil aeroszol oldatkészítmény
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
GEP20247642B (en) * 2020-02-20 2024-07-10 Chiesi Farm Spa Pressurised metered dose inhalers comprising buffered pharmaceutical formulation

Also Published As

Publication number Publication date
PE20240629A1 (es) 2024-03-26
AU2021356146A1 (en) 2023-05-04
IL301617A (en) 2023-05-01
AU2021356146A9 (en) 2024-06-27
EP4225267A1 (en) 2023-08-16
US20230277451A1 (en) 2023-09-07
CN116419749A (zh) 2023-07-11
JP2023546025A (ja) 2023-11-01
CL2023000998A1 (es) 2023-11-24
WO2022074183A1 (en) 2022-04-14
KR20230084482A (ko) 2023-06-13
CO2023004162A2 (es) 2023-04-17
CA3193038A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
MX2023003754A (es) Formulacion farmaceutica para inhalador presurizado de dosis medidas.
TW201129359A (en) Pharmaceutical composition for the treatment of COPD
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
CA2474479A1 (en) Composition for inhalation
JP2016040316A5 (es)
AR038641A1 (es) Formulacion superfina de formoterol
AR101593A2 (es) Formulación superfina de formoterol
DE60216588D1 (de) Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
MX2014004279A (es) Composiciones que comprenden sulfato de salbutamol.
ZA202208111B (en) Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
HRP20140550T1 (hr) Aerosolna formulacija za copd
WO2011076841A3 (en) Combination therapy for copd
MX2015014513A (es) Composicion que comprende sulfato de salbutamol.
MX2024002497A (es) Inhaladores de dosis medida y composiciones en solucion.
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
PE20011271A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
HRP20160630T1 (hr) Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata
JP2004529108A5 (es)
NZ600208A (en) Inhalation solutions
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
MX2022008440A (es) Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada.
CL2024003597A1 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas.
WO2004103339A3 (en) Improved metered dose inhaler
MX2021014343A (es) Una composicion de polvo inhalable de dosis fijas que comprende glicopirronio, formoterol y propionato de fluticasona.
PH12022551985A1 (en) Compositions and methods for delivering pharmaceutically active agents